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Abstract: Critics of the drug safety system have discussed many different potential reforms, 
ranging from mandatory registration of clinical trials to increasing the power of regulatory 
agencies, but few have discussed one of the most important ways of enhancing safety: increas-
ing the number of long-term studies of medications. Long-term studies of the risks and beneﬁ  ts 
of drugs can provide useful information for regulators, healthcare professionals, and patients. 
Government funding agencies should lead the effort to conduct long-term studies of drugs, but 
private companies should also be required to lend ﬁ  nancial support. Because cost-effectiveness 
is likely to be an important consideration in conducting this research, funding agencies should 
focus, at ﬁ  rst, on drugs that are used to treat common, chronic conditions.
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Public interest in reforming the drug safety system in the US has surged in recent 
years because of health risks related to medications approved by the Food and Drug 
Administration (FDA), which emerged after the drugs had been on the market for 
several years. Harmful reactions occurred with the use of the weight loss drug 
dexfenﬂ  uramine (Redux) in combination with phentermine, selective serotonin 
reuptake inhibitors (SSRIs) used to treat children or adolescents with depression, the 
diabetes medication rosiglitazone maleate (Avandia), and the arthritis medications 
rofecoxib (Vioxx) and celecoxib (Celebrex) (Couzin 2005). Vioxx was on the market 
for over ﬁ  ve years before Merck voluntarily withdrew the product due to safety (and 
liability) concerns. Ofﬁ  cials from Merck had evidence as early as November 1999 that 
Vioxx increases the risk of heart attacks and strokes. Merck reported this information to 
the FDA, but the company continued to market the drug without informing consumers 
or physicians about these risks. The FDA did not require Merck to change the labeling 
on Vioxx until 2002, when evidence concerning the cardiovascular risks of the drug 
continued to mount. The FDA also required the labeling to include a black box warn-
ing. In September 2004, Merck decided to pull the drug from the market. An estimated 
88,000 Americans had heart attacks while taking Vioxx, 38,000 of whom died. Over 
13,000 lawsuits involving Vioxx have been ﬁ  led against Merck (Prakash and Valentine 
2006). The Vioxx debacle triggered a Congressional inquiry into drug safety and the 
structure of the FDA. Several bills to address the issues have been drafted, but no 
legislation has passed thus far (Couzin 2005).
In the subsequent debate regarding drug safety, researchers, policy analysts, and 
healthcare professionals identiﬁ  ed many different problems that can compromise the 
quality and integrity of drug approval and oversight, including insufﬁ  cient public 
funding of the FDA, over-reliance on user fees to support the FDA, conﬂ  icts of interest 
on FDA advisory panels, management problems at the FDA, lack of transparency 
and openness in industry-sponsored studies, and inadequate post-marketing research Drug Design, Development and Therapy 2007:1 2
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and surveillance (Fontanarosa et al 2004; IOM 2006; Okie 
2005; Avorn 2007; McClellan 2007; Angell 2004; Resnik 
2007). Critics also put forth a number of different proposals 
for improving the drug safety system, such as increasing 
public funding for the FDA, enhancing the FDA’s regulatory 
authority, restructuring drug safety review within the FDA, 
mandatory registration of clinical trials, increasing the 
number of subjects in Phase II and Phase III trials, limiting 
direct-to-consumer advertising of drugs, and placing newly 
approved drugs on probationary status pending the outcome 
of post-marketing studies (IOM 2006; Strom 2006).
There is insufﬁ  cient space in this commentary to evaluate 
all of these various proposals for reforming the drug safety 
system: I refer the reader to discussions by other author (IOM 
2006; Strom 2006). Instead, this short essay will develop and 
defend a proposal for improving drug safety that is seldom 
mentioned in current policy debates: initiating more long-term 
studies of the risks of medications. A “long-term” study is one 
that gathers data on research subjects for 5 years or more. The 
US drug safety system is not designed to detect the long-term 
risks of medications. A typical Phase I trial may last 60 days or 
less, a Phase II study may take from a few months to a couple of 
years, and a Phase III trial usually last a couple of years at most 
(Centerwatch 2007). Although a new drug may go through 7 or 
more years of human testing before it is approved, this usually 
encompasses several separate studies, each of which might last 
anywhere from a few months to a couple of years. Most drug 
safety data from clinical trials and post-marketing studies are 
collected from subjects who have been exposed to a medication 
for less than a few years. However, some health risks do not 
materialize until a person has been exposed to a substance for 
5, 10, 15 or more years. For example, the average pack-a-day 
smoker will not develop lung cancer until they have smoked 
for at least 25 years (CDCP 2005). Some adverse health out-
comes occur many years after a brief exposure to a substance. 
For example, a person who inhales asbestos particles during 
a construction job might develop mesothelioma many years 
after this exposure (NCI 2007).
The medical literature contains some well-designed, 
useful studies of the long-term risks of medications, but even 
more long-term studies are warranted. For an example of 
one, consider the research conducted by Data Collection on 
Adverse Events of Anti-HIV Drugs (DAD) Study Group. The 
DAD investigators conducted a prospective observational 
study of 23,437 patients infected with HIV. They analyzed 
data on myocardial infarction (MI) and exposure to protease 
inhibitors and other anti-HIV medications, controlling for 
various factors than can affect the risk of MI, such as age, 
sex, body-mass index, blood pressure, smoking status, and 
blood cholesterol levels. 93.6% of the subjects in the study 
had taken protease inhibitors by the end of the study, with a 
median exposure of 6.9 years. The investigators found that 
the people exposed to protease inhibitors for 6 or more years 
are almost four times more likely to have an MI, as compared 
with people not exposed to protease inhibitors. They found 
that exposure to nonnucleoside reverse-transcriptase 
inhibitors did not increase the risk of MI (Friis-Møller and 
the DAD Study Group 2007).
The main argument for conducting additional stud-
ies of the long-term risks of drugs is that the information 
gained from this research can play an important role in 
health promotion and disease prevention. The FDA could 
use data from long-term drug studies to require changes in 
labeling or medication guidance, or even withdraw a drug. 
For example, the FDA changed its medication guidance and 
product labeling concerning SSRIs in response to studies 
showing that these drugs can increase the risk of suicidal 
thinking and behavior in children and adolescents (FDA 
2007a, 2007b). Physicians and patients can use the data from 
long-term studies to make decisions related to treatment or 
prevention. The knowledge gained from the DAD Study 
Group, for example, will play an important role in helping 
patients to reduce the risks of taking protease inhibitors and 
other anti-HIV medications. Patients who take protease 
inhibitors can try to counteract their increased risk of an MI 
by engaging in activities that can help to lower that risk, such 
as exercising, not smoking, and taking cholesterol-lowering 
drugs (if medically indicated). Some patients may decide to 
not take protease inhibitors, if other options for therapy are 
available.
Regulatory agencies do not currently have effective 
and reliable mechanisms for obtaining information about 
the long-term risks of drugs. As noted earlier, clinical trials 
gather data concerning risks that materialize from taking a 
drug for a couple of years, at most. The two mechanisms for 
collecting safety data after a drug is approved, post-marketing 
studies and the MedWatch program, are not systematic, 
thorough, or reliable. The FDA does not require companies 
to conduct or publish post-marketing studies. Consequently, 
drug manufacturers fail to complete post-marketing that 
they have agreed to perform more than 50% of the time, and 
they may fail to publish studies (Fontanarosa et al 2004). 
Moreover, even when post-marketing studies are performed 
and published, they last no more than a couple of years.
Under the MedWatch program, physicians and companies 
report adverse drug reactions (ADRs) to the FDA, which Drug Design, Development and Therapy 2007:1 3
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records and analyzes the data. Though companies are 
required by law to report ADRs they learn about, physi-
cians are not. Since physician reporting constitutes a major 
source of information for MedWatch, data collection under 
this program is sporadic and incomplete. Additionally, there 
may be adverse outcomes related to drugs that physicians 
and companies do not even think about reporting because 
they do not regard these outcomes as ADRs. For example, 
if a patient who has been taking a diabetes medication for 
ten years develops liver cancer, a physician will probably 
not view this health outcome as related to the medication, 
even though this may constitute evidence that the medication 
increases the risk of liver cancer.
With regard to the drugs mentioned at the beginning of 
this commentary, there is, admittedly, no direct evidence 
that long-term studies would have prevented the harms that 
occurred. However, long-term studies could have alerted 
researchers and regulators to some of the problems with 
these drugs before post-marketing studies sponsored by 
pharmaceutical companies or the MedWatch program had 
indicated a cause for concern. First, since companies are 
not required to publish the results of their post-marketing 
research, they could decide to suppress results that demon-
strate the harmful effects of their drugs. Indeed, there is some 
evidence that Merck suppressed or delayed publication of 
its post-marketing studies on Vioxx (Prakash and Valentine 
2006). A company would not have the authority to stop or 
delay the publication of a long-term study sponsored by an 
independent institution or agency. Second, since reporting of 
adverse drug reactions under MedWatch is not systematic, 
thorough, or reliable, it might take a long time for data 
generated from this program to demonstrate statistically 
signiﬁ  cant and harmful effects of a drug. A long-term study 
could detect these effects much earlier. Thus, while long-
term studies cannot prevent tragedies like Vioxx, Redux, and 
Avandia, they can help to minimize harm to the public.
One of the problems with conducting long-term studies 
of drugs is that they can be difﬁ  cult to design and implement. 
For ethical and practical reasons, experimental methods, such 
as randomized controlled trials (RCTs), are usually not a 
legitimate option for long-term medication studies. Subjects 
randomly assigned to a particular treatment regimen for 5 or 
more years or to a control placebo group (if allowed by the 
medical condition, drug, and study design) may decide to opt 
out of the study when a better treatment becomes available, or 
when they want to switch medications for some other reason 
(Levine 1988). In addition, following subjects for a long 
time can be logistically difﬁ  cult because the subjects might 
change phone numbers, addresses, pass away, or simply lose 
interest in the study. Any of these situations would lead to a 
high attrition rate, which could compromise the validity of 
the study (Gallin 2002). Additionally, experimental studies 
can be prohibitively expensive, because the sponsor would 
need to pay for the medication for 5 or more years.
Since an RCT might not be a legitimate option for a 
long-term drug study, investigators may have to use an 
observational (versus interventional) study design that can 
be either prospective or retrospective, conducted after FDA 
approval of the drug (Blair and Taylor 2007). Prospectively, 
investigators can collect and analyze data from both exposed 
and unexposed groups at regular intervals on the variables 
of interest, such as demographic characteristics, health 
status, morbidity, mortality, and so on. The DAD Study 
Group used a prospective cohort study design to examine 
the effects of anti-HIV medications. Other observational 
methods that might prove useful in long-term drug studies 
include retrospective cohort studies, and prospective and 
retrospective case-control studies (Blair and Taylor 2007).
Observational methods also have some problems. It can 
be difﬁ  cult to identify subjects that meet all study inclusion 
criteria. Retrospective observational methods might also 
require data abstraction from medical records that might 
not be complete or standardized across medical centers 
and reference laboratories. Furthermore, it can be difﬁ  cult 
to identify and control all of the factors that may affect the 
research subjects, and unknown factors might confound the 
data, giving investigators the impression that two variables 
are related when they are not. For example, if a cancer rate 
increases for several measurement intervals in a row while 
a subject is taking an experimental drug, it may appear that 
the drug is causing the cancer rate to increase, when, in 
fact, a confounding factor such as age, is responsible for the 
increased cancer rate. Another confounding factor may be the 
person’s disease status: as a person’s disease progresses, this 
may have some inﬂ  uence over the medications he chooses 
to take or his body’s response to those medications (Hughes 
and Williams 2007).
Even when investigators have been able to eliminate or 
account for confounding factors, it may be difﬁ  cult to develop 
statistically signiﬁ  cant associations between the characteristic 
being investigated and speciﬁ  c health outcomes, due to the 
large number of different variables. To show that exposure 
to a chemical increases the risk of cancer, for example, 
the analysis of the data must account for factors such as 
age, genetics/family history, smoking status, exposure to 
radiation and other chemicals, diet, and so on. Investigators Drug Design, Development and Therapy 2007:1 4
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can overcome this problem by using statistical methods that 
can account for many different variables, such as testing for 
confounders, analysis of variance, or multiple regression, 
and by ensuring that the sample size is large enough to 
yield the desired level of statistical signiﬁ  cance (Blair and 
Taylor 2007).
Increasing the sample size creates other practical 
problems, however, since the sample size may need to be 
very large (5,000 or more subjects) to achieve the goals of 
the study. The DAD Study Group gathered data on 23,437 
people exposed to antiretroviral drugs (Friis-Møller and the 
DAD Study Group 2007). Investigators from a National 
Institute of Environmental Health Sciences (NIEHS) project 
known as the Sister Study, plan to enroll 50,000 breast 
cancer-free sisters of women who have had breast cancer to 
understand how different environmental factors may increase 
the risk of this disease (NIEHS 2007). Increasing the size 
of study also increases its complexity and cost, and large 
observational studies can be very expensive and difﬁ  cult 
to administer (Blair and Taylor 2007). Cost need not be a 
deterrent to conducting long-term drug studies, but it does 
require research sponsors to make prudent choices concern-
ing funding. To make effective use of limited resources, it 
may be wise to focus, at ﬁ  rst, on drugs used to treat common, 
chronic diseases, such as arthritis, diabetes, hypertension, 
anxiety, and depression, since many people take drugs to treat 
these diseases for many years. When enough research has 
been conducted on common, chronic diseases, investigators 
can examine rarer ones.
The topic of money brings up another important problem 
concerning long-term drug studies: who will pay for them? 
Biomedical research and development (R and D) is supported 
primarily by private industry, which funds about 62% of 
biomedical R and D while the government funds about 31%. 
The remaining 7% of R and D funding comes from private 
foundations and universities (Resnik 2007). Pharmaceutical 
companies have no incentive to pay for long-term, post-
marketing studies that could link their medications to health 
risks. Once a drug is already on the market, a company’s main 
reason for funding additional research would be to compare 
the drug with competing drugs, or to determine whether the 
drug can be safely used in a manner different from its original 
approved use, eg, to treat a different medical condition or 
different population (Angell 2004).
If pharmaceutical companies are not likely to voluntarily 
sponsor long-term studies of drugs, then the ﬁ  nancial burden 
falls on the government, unless the Congress or regulatory 
agencies decide to require companies to sponsor long-term 
studies. In the US, the National Institutes of Health (NIH) 
is the main source of government support for biomedical 
research. Leaders of the NIH set funding priorities based 
on input from scientists, healthcare professionals, patient 
advocacy groups, members of the public, and, of course, 
politicians (Resnik 2001). NIH leaders use the disease burden 
concept to decide how much R and D to allocate toward 
speciﬁ  c diseases or research areas. Disease burden is multi-
faceted concept that attempts to capture that total burden that 
a disease places on society. It includes mortality, morbidity, 
loss of quality of life years, and social and economic costs 
(Resnik 2001).
While it is difﬁ  cult to estimate the burden related to 
the long-term adverse effects of medications, there is some 
evidence that it is substantial. First, as noted earlier, Vioxx, 
Redux, and many other medications have caused considerable 
harm after going on the market. If the cardiovascular 
problems related to Vioxx had occurred after ﬁ  ve or more 
years of exposure to the drug instead of less than two, the 
medical community might have never learned about the risk 
of Vioxx, or it might have learned about these risks only after 
thousands more people had been harmed. If drug-related 
harms can emerge after only a couple of years of exposure, 
it is likely that harms can emerge after a longer period of 
exposure. Second, ADRs are one of the leading causes of 
ill-health in the US, killing more than 100,000 people each 
year and seriously injuring more than 2 million (Public 
Citizen 2007). Though most ADRs are due to improper drug 
dosage or administration, dangerous drug interactions, and 
allergic responses drugs, it is likely that many are due to the 
long-term effects of drugs on the body.
These sobering facts form the threads of a sound policy 
argument for investing government funds in studies of 
the long-term effects of drugs: the government should 
spend money on this research to reduce the health burdens 
caused by the adverse effects of medications. Leaders of 
the NIH institutes with an interest in this problem, such 
as the NIEHS, the National Institute of General Medical 
Sciences (NIGMS), the National Heart, Lung and Blood 
Institute (NHLBI, and the National Cancer Institute 
(NCI) should each set aside some funds to jump-start 
research into the long-term studies of drugs. They may 
ask Congress for additional funds to cover this research, if 
necessary. Funds from different agencies could be pooled 
together to form an inter-agency group to assess evidence, 
develop research strategies and review research proposals. 
Additionally, private companies should be required to 
help fund this research by making a contribution to the Drug Design, Development and Therapy 2007:1 5
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government’s efforts. Drug approval could be contingent 
upon a commitment to contributing a percentage of funds 
to long-term drug studies.
In conclusion, long-term studies of the risks of drugs can 
and should play an important role in the drug safety system. 
Information gained from long-term drug studies can be 
useful to regulators, healthcare professionals, and patients. 
Though these studies are conducted from time to time, more 
are needed. Government funding agencies, such as the NIH, 
should lead the effort to conduct long-term studies of drugs, 
but private companies should also lend ﬁ  nancial support. 
Because cost-effectiveness is likely to be an important 
consideration in conducting this research, funding agencies 
should focus, at ﬁ  rst, on drugs that are used to treat common, 
chronic conditions. The funds used to conduct these studies 
will be money well spent.
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